Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections
The option was awarded under the company’s existing contract with BARDA that provides up to $132 million in support to advance development of the portfolio of new therapies.
- The option was awarded under the company’s existing contract with BARDA that provides up to $132 million in support to advance development of the portfolio of new therapies.
- “This award follows the important progress made in our programs since our merger with Shionogi last year,” said Michael N. Dudley, Pharm.D., President and CEO of Qpex.
- “The urgent, global threat of antimicrobial resistance demands innovation,” said John Keller, Ph.D., Senior Executive Officer, Senior Vice President, R&D Supervisory Unit at Shionogi.
- The Qpex senior leadership team worked together for more than a quarter century, and they have completed four regulatory approvals in the past decade.